ClinicalTrials.gg
RecruitingNCT03563417ISCHEMIA-CTOUpdated Jan 2, 2026

ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO

An interventional study of Percuteneous Coronary Intervention and Optimal Medical Therapy in Ischemic Heart Disease and Chronic Total Occlusion of Coronary Artery, sponsored by Aarhus University Hospital Skejby. Recruiting at 27 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2018; still recruiting 8 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Myocardial Ischemia with a site in Spain — 14 open to participants now, 26 under way, 1 of them phase 3. Myocardial Ischemia · Spain.

Planned enrollment
7th of 39
1,560 · median 324
Started
2018
with 4 others
No phase
22 of 76
5 open now
Primary completion
2028-11
later than 22 of 25 live
Registered
28th of 76
by date
Lead sponsor
2 of 76
Aarhus University Hospital Skejby

Among the 76 studies in Myocardial Ischemia with a site in Spain, this one is the 7th largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2018, is one of 22 with no phase, reaches primary completion later than 22 of the 25 other live ones, and was the 28th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

14 of the 76 studies in Myocardial Ischemia with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Myocardial Ischemia with a site in Spain, or all of them as a file.
02

Study summary

Study design

Prospective randomized open labeled multicenter study

Hypotheses

  1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI (Percutaneous Coronary Intervention) with latest generation of drug eluting stents is superior to optimal medical therapy in terms of relative reduction in MACCE (Major Adverse Cardiovascular and Cerebrovascular events).
  2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy (OMT) in terms of improved life quality measured as an increase of SAQ (Self Assessment Questionnaire) score of 8 points after 6 months.

Inclusion Criteria

  • CTO in native coronary artery
  • Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.
  • Age ≥18 yrs.
  • Able to provide written Informed consent and willing to comply with the specified follow-up contacts
  • Target artery ≥ 2.5 mm

Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:

Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL > 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO

Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO

Cohort C: patients enrolled but not randomized in cohort A or B

Exclusion criteria (for both cohort A and B)

  • NSTEMI or STEMI within 1 month
  • Coronary anatomy not suitable for CTO-procedure
  • Coronary artery disease involving the left main/three-vessel disease with indication for CABG following heart team conference
  • Life expectancy \< 2 years
  • Severe chronic pulmonary disease (FEV1 \< 30 % of predicted value)
  • Contraindication to dual anti-platelet therapy
  • Pregnancy
  • eGFR \< 30 mL/min/1.73 m2
  • In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.
  • Severe valvular heart disease

Primary endpoint

Cohort A: Composite endpoint of MACCE (all-cause mortality, stroke, any myocardial infarction, clinically driven revascularization*), hospitalization for heart failure or incidence of malignant arrhythmias.

*CCS class ≥ 2 and/or QoL score \< 60. Same criteria used as for allocation to Cohort B

Cohort B: SAQ Quality of Life Assessment after 6 months.

Number of patients

1,560 (1200 in cohort A/360 in cohort B

Follow up time

Cohort A: 5 years Cohort B: 6 months

Read the detailed description

A chronic total occlusion (CTO) is observed in up to (1) 30 % of patients undergoing diagnostic coronary angiography. The presence of a CTO is associated with worse outcome compared to non-occlusive coronary artery disease.

Percutaneous Coronary Intervention (PCI) treatment of CTO lesions has gained much attention over the last decade due to introduction of new techniques and devices resulting in high success rates in dedicated centers. However the scientific evidence is mainly based on observational studies and expert consensus. The current European and American guidelines on revascularization does not provide any clear recommendations how to manage patients with CTO.

The indication of treating a CTO lesion, or any other lesion with PCI for that matter, is either to relieve symptoms or improve prognosis. However, to date, there are no randomized clinical trials showing any prognostic benefit from CTO revascularization. Data from randomized clinical trials are also scarce regarding improvement of symptoms and Quality of life (QoL). In the recently presented DECISION-CTO study, patients were randomized to PCI vs. OMT, and the study failed to demonstrate a prognostic or symptomatic benefit of PCI vs. OMT. However, the study was prematurely terminated due to slow inclusion rate and had a high crossover rate and a high proportion did not have a quality of life score at follow-up. The fact that both the Decision CTO and the Euro CTO trial failed to include the pre-specified number of patients, makes it difficult to draw any conclusions on how to treat these patients. The preliminary results from both trials indicate that CTO PCI seems to be a safe procedure and might improve symptoms and QoL. In the randomized EXPLORE trial, patients with ST-elevation myocardial infarction (STEMI)and a concomitant CTO in a non infarct related artery was investigated. This study showed no benefit in terms of improving left ventricular function due to CTO-PCI of the concomitant CTO, although the procedure was safe.

Meta-analysis of observational studies comparing the prognosis after successful vs. unsuccessful CTO PCI indicate prognostic and symptomatic benefit of successful CTO PCI. However, these studies often lack data regarding ischemia burden and viability. The fact that the non-successful PCI patients consistently in these studies have higher risk profile, indicating the presence of residual confounders not accounted for in the multivariate statistical models, makes the interpretation of these data in a clinical setting difficult. The non-randomized FACTOR trial demonstrated a positive outcome for quality of life, but only in symptomatic patients. Data from the OPEN-CTO registry demonstrated an improvement of the Seattle Angina Questionnaire for quality of life by 10.8 points after a successful CTO-procedure. In addition to symptomatic improvement, a successful CTO procedure can reduce the amount of myocardium susceptible to ischemia in patients with at least mild to moderate ischemia at baseline and by that the prognosis can be improved (mortality, myocardial infarction, ventricular arrhythmias).

Hence, the interventional management of CTO lesions must address whether it is indicated on symptomatic and/or prognostic basis. These questions have not been sufficiently addressed in the previous trials and we need evidence from randomized clinical trials on how to treat these patients. We therefore designed this randomized clinical trial addressing the impact of CTO PCI on outcome. Patients are included in 2 different patient cohorts depending on level of symptoms and level of myocardial ischemia. From previous studies, we know that it is most probably only patients with at least moderate myocardial ischemia who will benefit from CTO PCI in terms of improving MACCE, and only symptomatic patients who will benefit with regard to improvement of quality of life following CTO PCI.

Before entering the study all patients will be subject to a 3-month period with titration of optimal medical therapy. Hereafter the patients will be eligible for inclusion in one of two cohorts based on level of ischemia and presence of symptoms:

Cohort A: Comprise CTO patients who are asymptomatic (CCS class \<2 and SAQ QoL> 60) but have moderate myocardial ischemia (>10% of the left ventricle) on MR or rubidium-PET. These patients will be randomized to CTO PCI or OMT and followed up to 10 years.

Cohort B: Comprise symptomatic CTO patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60) with at least 5% reversible ischemia. These patients will be randomized to CTO PCI or OMT. The patients randomized to OMT will be offered CTO PCI procedure 6 months after randomization following assessment of Seattle Angina Questionnaire quality of life score.

Cohort C - Patients enrolled but not eligible for randomization All patients enrolled at baseline but who do not meet the criteria described in cohort A and B for randomization. Registry based follow-up (optional) is performed at the same time points as in Cohort A.

This is the first randomized study that addresses improvement of prognosis and quality of life following PCI of CTO lesions specifically.

The purpose of this study is twofold:

  1. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients with significant myocardial ischemia (≥ 10%) without symptoms
  2. Investigate the outcome of PCI vs. optimal medical therapy of CTO lesions in patients with symptoms and mild to moderate myocardial ischemia (≥5%).

Hypotheses

  1. In asymptomatic patients with ≥ 10% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy in terms of outcome measured as 30% relative reduction in Major Adverse Cardiovascular and Cerebrovascular events (MACCE).
  2. In symptomatic patients with ≥ 5% of myocardial ischemia: PCI with latest generation of drug eluting stents is superior to optimal medical therapy in terms of improved life quality measured as an increase of SAQ score of 8 points after 6 months.
03

Conditions studied

  • Ischemic Heart Disease
  • Chronic Total Occlusion of Coronary Artery

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CTO in native coronary artery
  • Myocardial ischemia in a territory supplied by CTO assessed by nuclear imaging.
  • Age ≥18 yrs.
  • Able to provide written and willing to comply with the specified follow-up contacts.
  • Target artery ≥ 2.5 mm

Prior to randomization all patients undergo 3 months of OMT. Subsequently the population will be divided into:

Cohort A: Asymptomatic (CCS \< 2 and SAQ QoL > 60) patients with myocardial ischemia (≥ 10% of LV) in a territory supplied by CTO

Cohort B: Symptomatic patients (CCS class ≥ 2 and/or SAQ QoL score ≤ 60 after treating non CTO lesions and after OMT) with Myocardial ischemia (5% of LV) in a territory supplied a CTO assess by nuclear imaging.

Cohort C: Screening population not eligible for randomization in cohort A or B

Exclusion criteria

Exclusion Criteria:

  • NSTEMI or STEMI within 1 month
  • Coronary anatomy not suitable for CTO-procedure
  • Coronary disease involving the left main/three vessel disease with indication for CABG following heart team conference.
  • \< 2 years
  • Severe chronic pulmonary disease ( \< 30 % of predicted value)
  • to dual anti- therapy
  • Pregnancy
  • \< 30 mL/min/1.73 m2
  • In multi-vessel disease: if it is deemed unsafe to treat the non-CTO lesion first.
  • Severe valvular heart disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,560 participants (estimated)

Study arms

  • Active comparator
    PCI

    Procedure: Percuteneous Coronary Intervention

  • Other
    OMT

    Other: Optimal Medical Therapy

Interventions

  • ProcedurePercuteneous Coronary Intervention

    PCI of Chronic Total Occlusions

  • OtherOptimal Medical Therapy

    Initiation and titration of optimal medical therapy in the control arm.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cerebral and Cardiovascular Events

    Primary outcome in the Cohort A.

    Time frame: 5 Year

  2. Quality of life - Seattle Angina Questionnaire

    Primary outome in the Cohort B

    Time frame: 6 months

07

Study locations

14 of 27 sites recruiting
08

References and documents

Publications

  • Rinfret S, Sandesara PB. Reducing Ischemia With CTO PCI: Good News, But Questions Remain. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1419-1422. doi: 10.1016/j.jcin.2021.05.028. No abstract available. PubMed 34238552 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Nov 2028, 119 months after the start.

Of 155 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 56. This study's planned 119 months is above that.

Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2018
First posted
Jun 20, 2018
StartActual
Nov 6, 2018
Primary completionEst.
Nov 1, 2028
CompletionEst.
Nov 1, 2032
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03563417
Lead sponsor
Aarhus University Hospital Skejby
Responsible party
Evald Hoej Christiansen (Consultant MD PhD, Aarhus University Hospital Skejby) — Principal investigator
First posted
Jun 20, 2018
Start date
Nov 6, 2018
Primary completion
Nov 1, 2028 (estimated)
Completion
Nov 1, 2032 (estimated)
Last update
Jan 2, 2026

Study contacts

Evald Christiansen, MD PhD
Contact
evald.christiansen@dadlnet.dk
+45 78452028
Emil N Holck, MD
Contact
eh@clin.au.dk
+45 31419472
Evald Christiansen, MD PhD
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion